Stocks and Investing
Stocks and Investing
Tue, January 31, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Edward Nash Maintained (VTYX) at Strong Buy with Increased Target to $54 on, Jan 31st, 2023
Edward Nash of Canaccord Genuity, Maintained "Ventyx Biosciences, Inc." (VTYX) at Strong Buy with Increased Target from $35 to $54 on, Jan 31st, 2023.
Edward has made no other calls on VTYX in the last 4 months.
There are 3 other peers that have a rating on VTYX. Out of the 3 peers that are also analyzing VTYX, 0 agree with Edward's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Edward
- Jeff Jones of "Oppenheimer" Maintained at Buy with Increased Target to $60 on, Friday, January 27th, 2023
- Chris Shibutani of "Goldman Sachs" Initiated at Strong Buy and Held Target at $50 on, Monday, December 19th, 2022
- Simon Flannery of "Morgan Stanley" Initiated at Buy and Held Target at $45 on, Thursday, November 17th, 2022
Contributing Sources